Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?
|
|
- Susan Jocelyn Robbins
- 6 years ago
- Views:
Transcription
1 Coronary Revascularization in Patients witj Severe LV Dysfunction.: Implications of the STICH trial Is the concept of viability still viable? Banff
2 Prognosis of Patients With LV Dysfunction and CAD Major determinants Pt with CAD Pt with LV dysfunction Severity of LV dysfunction Results of revascularization a paradox and a window of opportunity Periprocedural risk Severity of CAD/ischemia Late mortality 2016 MFMER
3 Probability of death from any cause STICH Trial Outcomes 1,212 pt EF <0.35 CCS angina 2 (95%) NYHA 3 (97%) All Cause Mortality H Ratio % CI P=0.12 MED CABG Years since randomization Velasquez: NEJM, MFMER
4 Probability of death from CV causes Probability of death from any cause or hospitalization for CV causes CV Mortality and CHF Hospitalization CV Mortality H.R % CI P= All-Cause Mortality and CHF Hospitalization H.R % CI P< MED 0.4 MED 0.4 CABG 0.2 CABG Years since randomization Years since randomization Velasquez: NEJM, MFMER
5 Definition of Viable Myocardium Myocardium that is dysfunctional at rest and not scarred and has the potential for functional recovery Hibernation should be used retrospectively only to describe those segments which actually improve following revascularization Shah: EHJ, MFMER
6 Viability and Prognosis in Patients with LV Dysfunction Different Substrates Hibernation (resting ischemia) Repetitive stunning (inducible ischemia) Extent of scar Extent of remodeling Duration of hibernation How much is enough not an all or none issue Need for combined imaging approaches to characterize substrates and reversibility 2015 MFMER
7 % Viable/total myocardium Quantity of Viable Myocardial Required to Improve Survival With Revascularization in Patients With Ischemic Cardiomyopathy 29 studies 4,167 patients Meta-analysis Optimal Threshold for Presence of Viability PET Stress Echo SPECT Inaba: J NuclCardiol, MFMER
8 Clinical Indications for Viability Testing Severe CAD and no history of MI Absent Q waves on ECG Significant angina or stressinduced ischemia Patients with CAD and severe LV dysfunction (EF 0.35) Flash pulmonary edema with subsequent improvement Angiography Subtotal occlusions Collaterals Clinical EF? 2015 MFMER
9 Weighted average annual mortality (%) Viability Testing and Mortality After Treatment 14 nonrandomized studies Medical therapy Revascularization 0 Viability present Viability absent Camici: Circ, MFMER
10 Probability of death STICH Myocardial Viability and Survival 601 pt viability testing SPECT DSE Hazard ratio % CI P=0.003 Without viability (114 pt) With viability (487 pt) Years since randomization Bonow: NEJM, MFMER
11 STICH Myocardial Viability and Survival Subgroup No. Deaths HR (95% CI) P Without ( ) 0.53 viability With ( ) viability CABG better Medical therapy better Mortality Variable Chi-square P RAR score <0.001 LVEF <0.001 LVED volume index <0.001 LVES volume index <0.001 Myocardial viability Bonow: NEJM, MFMER
12 Patients Randomized in STICH Revascularization Hypothesis 1,212 SPECT n=471 Dobutamine echo n=280 Patients with usable myocardial viability test Viable Nonviable 611 Patients with no usable myocardial viability test Bonow et al: NEJM, MFMER
13 STICH Viability Study Limitations Study is underpowered Non-randomized viability performed at physician discretion and unblinded Baseline differences between pt with/without viability testing comorbidities Generalizability to contemporary population ICD 50% CRT 20% 85% of patients in substudy non-usa 3 VD only present in approximately one third Viability determined in a binary fashion PET and CMRI greater accuracy and provide additional information Does not distinguish between dysfunctioning viable myocardium and reversibility 2016 MFMER
14 Role of Viability Testing in Clinical Decision Making in Patients With LV Dysfunction Not Essential Significant angina Good distal vessels ECG No Q waves Preserved voltage Reasonable surgical risk Helpful Severe LV dysfunction Extensive LV remodeling Multiple comorbidities Incomplete revascularization is likely Angina less severe 2016 MFMER
15 Mortality rate Inducible Myocardial Ischemia and Outcomes of Revascularization STICH Trial EF <0.35 Stress testing Inducible ischemia 64% % ischemic myocardium (18±11%) No Ischemia Mortality Ischemia MED (31 events) MED (56 events) CABG (22 events) Years following randomization CABG (47 events) Years following randomization Panza: JACC, MFMER
16 Log hazard ratio Impact of Ischemia and Scar on Therapeutic Benefit from Coronary Revascularization 13,969 pt Adenosine or exercise SPECT Role of ischemia in pt with >10% fixed myocardial defect % ischemic myocardium = P=0.089 Ischemia treatment interaction = P= P< Total myocardium ischemic (%) Medical therapy Early revascularization Hachamovich: EHJ, MFMER
17 Log hazard ratio Impact of Ischemia and Scar on Therapeutic Benefit from Coronary Revascularization 13,969 pt Adenosine or exercise SPECT Role of ischemia on benefit of revascularization was nullified by presence of extensive infarction/scar P< Total myocardium ischemic (%) Medical therapy Early revascularization Hachamovich: EHJ, MFMER
18 Jolicover et al Presence of angina does not confer markedly worse prognosis or a greater benefit from revascularization by CABG But CABG does improve angina symptoms compared with medical therapy alone 2015 MFMER
19 Is There a Role for Viability and Ischemia Testing? Is the Concept Still Valid and Rational? STICH patients Other patient subgroups No No effect of viability, inducible ischemia and angina on surgical outcomes remodeling with non-viability but no effect on surgical outcomes Bonow: NEJM, 2011; Panza: JACC, 2012 Jolicover: JACC, 2015; Bonow: JACC, 2015 Yes 2015 MFMER
20 Role of Viability Testing- Conclusions Ongoing trials may be pivotal : (AIMI HF) May predict response to revascularization in selected pts with CAD and LV dysfunction Marker of prognosis May influence response to medical therapy Impact of viability and residual ischemia may be overwhelmed by extensive scar and remodeling. Should not be a routine determinant of decision to revascularize 2015 MFMER
Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?
Coronary Revascularization for Severe LV Dysfunction Is s Is the concept of viability testing still viable? Banff 2017 2015 MFMER 3492638-7 Prognosis of Patients With LV Dysfunction and CAD Major determinants
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationSevere Left Ventricular Dysfunction: Evolving Revascularization Strategies
Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern
More informationRational use of imaging for viability evaluation
EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium
More informationCardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute
Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute 62 year old male Anterior STEMI late presentation, occluded
More informationEvaluation of Myocardial Viability: What Have We Learned from STICH? Professor of Medicine David Geffen School of Medicine at UCLA. Heart Failure (HF)
Evaluation of Myocardial Viability: What Have We Learned from STICH? Daniel S. Berman, MD Director, Cardiac Imaging Cedars-Sinai Heart Institute CSMC 2013 Professor of Medicine David Geffen School of Medicine
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationSung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center
CMR Perfusion and Viability A STICH Out of Time? Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center Can Imaging Improve
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationRevascularization In HFrEF: Are We Close To The Truth. Ali Almasood
Revascularization In HFrEF: Are We Close To The Truth Ali Almasood HF epidemic 1-2% of the population have HF At least one-half have heart failure with reduced ejection fraction (HF- REF) The most common
More informationAssessment of Ischemia and Viability
EAE Teaching Course Bucharest, 2010 Assessment of Ischemia and Viability Jens-Uwe Voigt Dpt. of Cardiology University Leuven Belgium Assessment of Ischemia & Viability resting wall motion Stress Testing
More informationRevascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability
Revascularization for Patients with HFrEF: CABG and PCI and the Concept of Myocardial Viability 22nd Annual Heart Failure 2018: an Update on Therapy April 2018 Eric J. Velazquez, MD, FACP, FACC, FASE,
More informationImaging in Ischemic Heart Disease: Role of Cardiac MRI
Imaging in Ischemic Heart Disease: Role of Cardiac MRI Chiara Bucciarelli Ducci MD, PhD, FESC, FRCP Consultant Senior Lecturer Cardiologist Bristol Heart Institute, University of Bristol, UK Chair elect,
More informationMyocardial viability testing. What we knew and what is new
Myocardial viability testing. What we knew and what is new Dr B K S Sastry, MD, DM. CARE Hospitals, Hyderabad What is Viability Viability Dysfunctional myocardium subtended by diseased coronary arteries
More informationJ. Schwitter, MD, FESC Section of Cardiology
J. Schwitter, MD, FESC Section of Cardiology CMR Center of the CHUV University Hospital Lausanne - CHUV Switzerland Centre de RM Cardiaque J. Schwitter, MD, FESC Section of Cardiology CMR Center of the
More information1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and
1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,
More informationWhat the Cardiologist needs to know from Medical Images
What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there
More informationImaging and heart failure
Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,
More informationHigh Risk PCI for Heart Failure
High Risk PCI for Heart Failure Ray Matthews MD Professor of Clinical Medicine Chief, Division of Cardiovascular Medicine University of Southern California Los Angeles, California Disclosures Abiomed Research
More informationRevascularization Strategies in Patients with Severe LV Dysfunction
Revascularization Strategies in Patients with Severe LV Dysfunction Richard Lee, M.D., M.B.A. Saint Louis University The Center for Comprehensive Cardiovascular Care C4 Severe LV Dysfunction Defined as
More informationInsights into Viability- Function and Contractile Reserve
Insights into Viability- Function and Contractile Reserve Tom Marwick Cleveland Clinic Conflicts research grants and consulting with GE, Philips, Siemens Off-label use of Definity for assessment of myocardial
More informationThe Role of SPECT/ PET
Session 15: Imaging Heart Failure The Role of SPECT/ PET Albert Flotats, MD, FEBNM Hospital de la Santa Creu i Sant Pau, Barcelona Universitat Autònoma de Barcelona HF - Clinical Questions 1. Etiology?
More informationManagement of High-Risk CAD : Surgeons Perspective
Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior
More informationThe Role of Nuclear Imaging in Heart Failure
The Role of Nuclear Imaging in Heart Failure Mouaz H. Al-Mallah, MD MSc FESC Associate Professor of Medicine Consultant Cardiologist and Division Head, Cardiac Imaging King Abdulaziz Cardiac Centre, National
More informationOld and new insights into viability:perfusion and Perfusion Reserve
Old and new insights into viability:perfusion and Perfusion Reserve R.Senior Professor of Clinical Cardiology Consultant Cardiologist and Director of Echo,Royal Brompton Hospital,London and Northwick Park
More informationClinical Considerations for CTO Revascularization
Clinical Considerations for CTO Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD, FACC, FSCAI Chief Medical Officer Cordis Cardiology Johnson & Johnson
More informationAssessment Of Myocardial Viability
Assessment Of Myocardial Viability James K. Min, MD FACC President, Society of Cardiovascular Computed Tomography Associate Professor of Medicine, UCLA School of Medicine Associate Professor of Medicine
More informationESC CONGRESS 2010 Stockholm, august 28 september 1, 2010
ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010 CORONARY ARTERY DISEASE AND NUCLEAR IMAGING: AN UPDATE PERFUSION SCINTIGRAPHY IN HIGH-RISK ASYMPTOMATIC PATIENTS Pasquale Perrone Filardi Federico
More informationViability Testing Using Dynamic Echocardiography
Viability Testing Using Dynamic Echocardiography Theodora A Zaglavara, MD, PhD Director of Echocardiography EUROMEDICA KYANOUS STAVROS HOSPITAL Thessaloniki GREECE Goals of Cardiac Imaging in Coronary
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationMR Assessment of Myocardial Viability
MR Assessment of Myocardial Viability Definition of Viability Clinical Metabolism: Presence of glucose uptake Perfusion / Perfusion reserve Morphology: Wall thickness, wall thickening Contractility: Recovery
More information@02-126_Coronary_calcification.ppt. Professor Molecular and Medical Pharmacology
Assessment of Myocardial Viability Jamshid Maddahi, M.D., FACC, FASNC Professor Molecular and Medical Pharmacology (Nuclear Medicine) and Medicine (Cardiology) David Geffen School of Medicine at UCLA Director,
More informationIschemic Heart Failure
15 th Cardiology Congress of Northern Greece Thessaloniki, May 26-28, 2016 Ischemic Heart Failure Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationRevascularization of ischemic LV dysfunction: past, present and future
Revascularization of ischemic LV dysfunction: past, present and future Paolo G Camici, MD, FESC, FACC, FAHA, FRCP Vita-Salute University and San Raffaele Scientific Institute Milan Advances in Cardiovascular
More informationCardiogenic Shock. Carlos Cafri,, MD
Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and
More informationRadiologic Assessment of Myocardial Viability
November 2001 Radiologic Assessment of Myocardial Viability Joshua Moss, Harvard Medical School Year III Patient EF 66yo female with a 3-year history of intermittent chest pain previously relieved by sublingual
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationCoronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art
Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art Harisios Boudoulas, MD, Dr, Dr. Hon. Professor, Honorary Professor, Academician Development of Coronary Artery
More informationCardiovascular Imaging Stress Echo
Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established
More informationClinical Considerations for CTO
38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research
More informationAll in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, MFMER
ICD for NICM All in the Past? Win K. Shen, MD Mayo Clinic Arizona Controversies and Advances in CV Diseases Cedars-Sinai Heart Institute, 2017 2017 MFMER 3686275-1 DISCLOSURE Relevant Financial Relationship(s)
More informationClinical Summary. Live Cases I - IX
Clinical Summary Live Cases I - IX Case #1 2017/09/16 Age: 66 Target Vessel: RCA proximal Relevant Diagnosis: Single vessel CAD with normal LVEF Coronary Risk Factors: Hypertension, smoke (90py) ECG abnormality:
More informationStable Angina: Indication for revascularization and best medical therapy
Stable Angina: Indication for revascularization and best medical therapy Cardiology Basics and Updated Guideline 2018 Chang-Hwan Yoon, MD/PhD Cardiovascular Center, Department of Internal Medicine Bundang
More informationCHRONIC CAD DIAGNOSIS
CHRONIC CAD DIAGNOSIS Chest Pain Evaluation 1. Approach to diagnosis of CAD 2. Classification of chest pain 3. Pre-test likelihood CAD 4. Algorithm for chest pain evaluation in women 5. Indications for
More informationCardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018
Cardiac MRI: Detection of Ischemia Cardiac MRI in Today s Clinical Practice Foundations of Cardiovascular Magnetic Resonance Daniel C. Lee, MD, MSc Assistant Professor of Medicine and Radiology Co-Director,
More informationIschemic Heart Failure
Kalymnos Days Hellenic Cardiological Society Kalymnos, June 11, 2016 Ischemic Heart Failure Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University
More informationLow Gradient Severe? AS
Low Gradient Severe? AS Philippe Pibarot, DVM, PhD, FACC, FAHA, FESC, FASE Canada Research Chair in Valvular Heart Diseases Institut Universitaire de Cardiologie et de Pneumologie de Québec / Québec Heart
More informationThe Value of Stress MRI in Evaluation of Myocardial Ischemia
The Value of Stress MRI in Evaluation of Myocardial Ischemia Dr. Saeed Al Sayari, MBBS, EBCR, MBA Department of Radiology and Nuclear Medicine Mafraq Hospital, Abu Dhabi United Arab Emirates Introduction
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationRole of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이
Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이 Outline Evaluation of Chest pain Evaluation of MI complications Prediction of Outcomes Evaluation of Chest pain Evaluation
More informationManagement of ST-elevation myocardial infarction Update 2009 Late comers: which options?
European Society of Cardiology Annual Session 2009 Management of ST-elevation myocardial infarction Update 2009 Late comers: which options? Antonio Abbate, MD Assistant Professor of Medicine Virginia Commonwealth
More informationCABG alone. It s enough? / Μόνο η αορτοστεφανιαία παράκαμψη είναι αρκετή;
LV Aneurysm and VSD in Ischaemic Heart Failure / Στεφανιαία νόσος, ανεύρυσμα αριστεράς κοιλίας και VSD CABG alone. It s enough? / Μόνο η αορτοστεφανιαία παράκαμψη είναι αρκετή; THEODOROS KARAISKOS CONSULTANT
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationCMR stress Perfusion: what's new?
CMR stress Perfusion: what's new? John P. Greenwood Professor of Cardiology, Leeds University, UK Consultant Cardiologist Leeds Teaching Hospitals NHS Trust, UK CMR: multi-parametric CMR: multi-parametric
More informationPearls & Pitfalls in nuclear cardiology
Pearls & Pitfalls in nuclear cardiology Maythinee Chantadisai, MD., NM physician Division of Nuclear Medicine, Department of radiology, KCMH Principle of myocardial perfusion imaging (MPI) Radiotracer
More informationRole of Ablation of AF and PVCs in the Management of Heart Failure
Role of Ablation of AF and PVCs in the Management of Heart Failure Cara Pellegrini, MD, FHRS Acting Chief, Cardiology, SF VA Associate Professor of Medicine, UCSF Disclosures I have nothing to disclose
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationCardial MRI; Approaching the Level of Gold Standard for Viability Assessment
Cardial MRI; Approaching the Level of Gold Standard for Viability Assessment 용환석 고려대학교구로병원영상의학과 Viability Hibernating myocardium a state of myocardial hypocontractility during chronic hypoperfusion, in
More informationI have no financial disclosures
Manpreet Singh MD I have no financial disclosures Exercise Treadmill Bicycle Functional capacity assessment Well validated prognostic value Ischemic assessment ECG changes ST segments Arrhythmias Hemodynamic
More informationTesting the Asymptomatic CAD Patient: When and Why?
Testing the Asymptomatic CAD Patient: When and Why? Timothy M. Bateman M.D. Co-Director, Cardiovascular Radiologic Imaging Mid America Heart Institute Professor of Medicine University of Missouri-Kansas
More informationImplications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationWho is the high risk patient?
Who is the high risk patient? High risk of periprocedural death or other major complications (hemodynamic compromise, MI, stroke, dialysis) Contributors of Risk Lesion/Procedure Governed by 1. Patient
More informationWelcome! To submit questions during the presentation: or Text:
Welcome! To participate in the interactive Q & A please do the following: 1. Download the Socrative Student App 2. Enter Teacher s Room Code: ZD0F3X5Q 3. Select Quiz: Intermountain Cardiac Stress Testing
More informationCorrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio
Corrective Surgery in Severe Heart Failure Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio Session Objectives 1.) Identify which patients with severe
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationCurrent Indications for Cardiac MRI: What You See is What You Get?
Current Indications for Cardiac MRI: What You See is What You Get? Javier Ganame, MD, PhD, FASE No disclosures Cardiology Update, Niagara, Sept 24th, 2016 The Ideal Diagnostic Technique Easy to apply Accurate
More informationDiagnosis of CAD S Richard Underwood
Diagnosis of CAD S Richard Underwood Professor of Cardiac Imaging Royal Brompton Hospital & Imperial College Faculty of Medicine London, UK The history and diagnosis 89% Non-cardiac chest pain 50% Atypical
More informationImportance of CRT team for optimization of the results: a European point of view
Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationClinical Summary. Live Cases I - IX
Clinical Summary Live Cases I - IX Patient: Male, 66 years Diagnosis: Single vessel CAD with normal LVEF Target lesion: proximal RCA Coronary risk factor: Hypertension, smoke (90py) Clinical course: ECG
More informationImaging Saves Lives: An Evidence-Based Choice of Modality Magnetic Resonance Imaging
Imaging Saves Lives: An Evidence-Based Choice of Modality Magnetic Resonance Imaging Oliver Bruder Department of Cardiology Elisabeth Hospital Essen Germany Growth of CV Imaging Shaw; JACCi 2010 Novel
More informationSPECT TRACERS Tl-201, Tc-99m Sestamibi, Tc-99m Tetrofosmin
SPECT TRACERS Tl-201, Tc-99m Sestamibi, Tc-99m Tetrofosmin Elmer Jasper B. Llanes, M.D. Nuclear Cardiology St. Luke s Medical Center Outline Ideal Physiologic Characteristics of MPI radioactive tracers
More informationParis, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators
Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo
More informationChronic Total Occlusion: A case for coronary artery bypass grafting
Chronic Total Occlusion: A case for coronary artery bypass grafting Prof. Alfredo R Galassi MD, FESC, FACC, FSCAI Director of Cardiac Catheterization and Interventional Cardiology Unit Department of Medical
More informationpresenters 2010 Sameh Sabet Ain Shams University
Guidelines for PCI in late STEMI presenters 2010 Sameh Sabet Assistant Professor of Cardiology Ain Shams University 29% of MI patients have STEMI. NRMI 4 (Fourth National Registry of Myocardial Infarction),
More informationTrial. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches
Trial International Study of Comparative Health Effectiveness with Medical and Invasive Approaches Stable Ischemic Heart Disease What is the best initial management strategy for patients with SIHD? What
More informationEcho in CAD: Wall Motion Assessment
Echo in CAD: Wall Motion Assessment Joe M. Moody, Jr, MD UTHSCSA and STVHCS October 2007 Relevant References ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography Bayes de
More informationTopic. Updates on Definition of Myocardial Infarction
Topic Updates on Definition of Myocardial Infarction In the past, general consensus for MI? Definition of MI by WHO - Combination of 2 of 3 characteristics - 1. Typical Symptoms 2. Enzyme Rise 3. Typical
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationChronic Total Occlusions. Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute
Chronic Total Occlusions Stephen Cook, MD Medical Director, Cardiac Catheterization Laboratory Oregon Heart & Vascular Institute Financial Disclosures /see -tee-oh / abbr. Med. Chronic Total Occlusion,
More informationNo Conflict of Interests
No Conflict of Interests Disclosure PI of Study Divaka Perera Senior Lecturer and Consultant Cardiologist St Thomas Hospital Campus, King s College London Heart Failure Management: Evidence Based Medicine
More informationHow does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE
How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? Prof. Patrizio LANCELLOTTI, MD, PhD GIGA Cardiovascular Sciences, Heart Valve Clinic, University of Liège, CHU
More informationImaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD
Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic
More informationTypical chest pain with normal ECG
Typical chest pain with normal ECG F. Mut, C. Bentancourt, M. Beretta Nuclear Medicine Service, Asociacion Española Montevideo, Uruguay Clinical history Male 41 y.o. Overweight, hypertension, high cholesterol,
More informationCASES IN ADVANCED IMAGING
CASES IN ADVANCED IMAGING DAVID A. ORSINELLI, MD PROFESSOR, CLINICAL INTERNAL MEDICINE THE OHIO STATE UNIVERSITY DIVISION OF CARDIOVASCULAR MEDICINE OHIO ACC ANNUAL CONFERENCE OCTOBER 2010 WHICH IMAGING
More informationHybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future
Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future Prof. Juhani Knuuti, MD, FESC Turku, Finland Disclosure: Juhani Knuuti, M.D. Juhani Knuuti, M.D. has financial
More informationMultimodality Imaging in Spontaneous Coronary Artery Dissection in the Peripartum Period
Multimodality Imaging in Spontaneous Coronary Artery Dissection in the Peripartum Period Marysia Tweet, MD NASCI Annual Meeting October 18 th, 2016 2016 MFMER slide-1 DISCLOSURE No relevant financial relationship(s)
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationRole of Stress Echo in Valvular Heart Disease. Satoshi Nakatani Osaka University Graduate School of Medicine Osaka, Japan
Role of Stress Echo in Valvular Heart Disease Satoshi Nakatani Osaka University Graduate School of Medicine Osaka, Japan Exercise echocardiography Dobutamine echocardiography Usefulness of exercise echo
More informationThe use of Cardiac CT and MRI in Clinical Practice
The use of Cardiac CT and MRI in Clinical Practice Matthew W. Martinez, MD Assistant Professor of Medicine LVPG - Lehigh Valley Heart Specialists Lehigh Valley Health Network Oct. 3, 2009 DISCLOSURE Relevant
More informationImaging in dilated cardiomyopathy : factors associated with a poor outcome
Imaging in dilated cardiomyopathy : factors associated with a poor outcome Johan De Sutter, MD, PhD, FESC AZ Maria Middelares Gent and University Gent - Belgium Dilated cardiomyopathy Cardiomyopathy with
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationNUCLEAR CARDIOLOGY UPDATE
Nuclear Cardiology David K. Shelton, Jr., MD NUCLEAR CARDIOLOGY UPDATE No Conflicts. No Disclosures. No Smoking. David K. Shelton UCDMC Nuclear Cardiology Nuclear Cardiology Radionuclide Ventriculography
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationPotential recommendations for CT coronary angiography in athletes
Potential recommendations for CT coronary angiography in athletes B.K. Velthuis Dept. of Radiology UMC Utrecht, the Netherlands EuroPRevent 15 April 2011 Declaration of interest Philips Medical Systems
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More information